FTC’s M&A crack­down; NASH drug gets thumbs down; FDA OKs top­i­cal gene ther­a­py; Com­pa­ny ex­its frus­trate rare dis­ease fam­i­lies; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER